
    
      Patients should have been treated with bevacizumab plus chemotherapy as a 1st line treatment,
      and after 1st progression, these patients will be accrued in this study of bevacizumab plus
      chemotherapy as a 2nd line treatment, and the combined chemotherapy will be chosen by
      physician's decision in consider with previous chemotherapy.
    
  